肥胖、年龄与合并症对类风湿关节炎多生物标志物疾病活动度检测的影响
基于Corrona注册的横断面分析纳入357例有MBDA检测的RA患者,76%患者CRP正常但MBDA仍可分层疾病活动度。MBDA评分与BMI、年龄、CDAI及SJC显著相关,与纤维肌痛、糖尿病、吸烟或COPD无关。在CDAI缓解患者中,高龄和肥胖独立关联MBDA评分,并提出校正MBDA评分与原评分高度相关(r=0.91)。
要点
- CRP正常的RA患者中约三分之一MBDA评分仍显示高疾病活动度。
- MBDA评分与BMI、年龄、CDAI和SJC显著相关,常见合并症影响可忽略。
- CDAI缓解患者中高龄和肥胖独立关联MBDA评分,建议校正BMI和年龄。
核心结论
- MBDA评分与RA疾病活动度、肥胖和年龄相关,受常见合并症影响很小。
- CRP正常患者中近三分之一MBDA评分高,提示MBDA可补充传统炎症标志物。
- 提出校正BMI和年龄的MBDA评分,与原MBDA高度相关(r=0.91)。
研究设计与样本
- 基于Corrona注册数据的横断面分析,纳入357例有MBDA检测的RA患者。
- MBDA评分分为低(<30)、中(30-44)和高(>44),用回归评估与年龄、BMI、合并症及RA相关因素的关联。
主要发现
- 357例中76%(n=273)CRP正常(<10mg/L),其MBDA疾病活动度为高33%、中45%、低22%。
- MBDA评分与BMI、年龄、CDAI和SJC显著相关。
- MBDA评分与纤维肌痛、糖尿病、吸烟或COPD无关联,均非MBDA与SJC或CDAI之间的混杂因素。
- CDAI缓解患者中,年龄每增加十年MBDA评分增加2.6单位(p=0.03);BMI>30(参照<25)的β=10.5(p=0.02)。
关键数值与推荐
- MBDA评分分层:低<30、中30-44、高>44。
- CRP正常定义为<10mg/L。
- CDAI缓解患者中,年龄每十年MBDA增加2.6单位(p=0.03),BMI>30的β=10.5(p=0.02)。
- 校正MBDA评分与原MBDA评分相关系数r=0.91。
临床怎么用
- 对CRP正常但临床怀疑活动度的RA患者,可考虑MBDA检测辅助评估。
- 解读MBDA评分时需考虑BMI和年龄影响,尤其CDAI缓解患者。
- 常见合并症(纤维肌痛、糖尿病、吸烟、COPD)对MBDA评分影响小,解读时不必过度校正。
局限性
- 横断面分析,无法推断因果关系。
- 样本来自Corrona注册,可能存在选择偏倚。
- 校正MBDA评分仅为提出,尚未外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Traditional markers of inflammation are often required for inclusion in rheumatoid arthritis trials, yet patients with active disease may have normal lab tests. The potential use of the multi-biomarker disease activity (MBDA) test in this setting is unclear, as is understanding of whether it is influenced by patient characteristics (e.g., age, BMI, and comorbidities). METHODS: Using data from the Corrona registry, we conducted a cross-sectional analysis of RA patients with MBDA tests. Patients were classified as low (<30), moderate (30-44, and high (>44) and by clinical and RA-related factors. Regression was used to evaluate the association between MBDA score and age, body mass index, comorbidities, and RA-related factors. RESULTS: Of 357 eligible patients, 76% (n = 273) had normal CRP (<10mg/L) with high (33%), moderate (45%), and low (22%) disease activity by MBDA. The MBDA score was significantly associated with BMI, age, CDAI, and SJC. There was no association between MBDA score and fibromyalgia, diabetes, smoking, or COPD; none were confounders between MBDA score and either SJC or CDAI. For patients in CDAI remission, older age (2.6 units per decade; p = 0.03) and obesity (β = 10.5 for BMI > 30, referent to <25; p = 0.02) were independently associated with MBDA score. An adjusted MBDA score was proposed that was highly correlated with the original MBDA (r = 0.91). CONCLUSION: In this real-world analysis, the MBDA score was associated with RA disease activity, obesity, and age, and was negligibly affected by common comorbidities. Almost one-third of patients with normal CRP had high MBDA scores. An adjustment to the MBDA score to account for body mass index and age is proposed.
引用
- Curtis JR, Greenberg JD, Harrold LR, et al. Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. Semin Arthritis Rheum. 2017. PMID: 28947312. doi:10.1016/j.semarthrit.2017.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。